Chronic hepatitis B virus (HBV) infection is a common cause of liver disease globally, with a
disproportionately high burden in South-East Asia. Vaccines and nucleoside or nucleotide …

Hepatitis B virus (HBV) specifically infects hepatocytes and causes severe liver diseases.
The HBV life cycle is unique in that the genomic DNA (relaxed-circular partially double …

Conclusions HBV cccDNA minichromosomes in distinct epigenetic transcriptional states
showed a similar reduction rate during cell division but significantly differed in their …

At least 250 million people worldwide are chronically infected with HBV, a small
hepatotropic DNA virus that replicates through reverse transcription. Chronic infection …

Background & Aims Viral clearance involves immune cell cytolysis of infected cells.
However, studies of hepatitis B virus (HBV) infection in chimpanzees have indicated that …

Hepatitis B virus (HBV) is a significant global pathogen, infecting more than 240 million
people worldwide. While treatment for HBV has improved, HBV patients often require …

The majority of persons currently treated for chronic hepatitis B require long‐term or lifelong
therapy. New inhibitors of hepatitis B virus entry, replication, assembly, or secretion and …

Hepatitis B virus (HBV) infection represents a significant public health burden worldwide.
Although current therapeutics manage to control the disease progression, lifelong treatment …

HBV deposits a covalently closed circular DNA form, called cccDNA, in the nucleus of
infected cells. As the central transcription template, the cccDNA minichromosome is a key …

Interferon (IFN) stimulates a whole repertoire of cellular genes, collectively referred to as
ISGs (Interferon-stimulated genes). ISG20, a 3´-5´ exonuclease enzyme, has been …